GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qurient Co Ltd (XKRX:115180) » Definitions » Institutional Ownership

Qurient Co (XKRX:115180) Institutional Ownership : 1.44% (As of May. 09, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Qurient Co Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Qurient Co's institutional ownership is 1.44%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Qurient Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Qurient Co's Float Percentage Of Total Shares Outstanding is 0.00%.


Qurient Co Institutional Ownership Historical Data

The historical data trend for Qurient Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qurient Co Institutional Ownership Chart

Qurient Co Historical Data

The historical data trend for Qurient Co can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30
Institutional Ownership 1.62 1.61 1.61 1.58 1.58 1.48 1.36 1.36 1.36 1.44

Qurient Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Qurient Co Business Description

Traded in Other Exchanges
N/A
Address
C-dong 8th Floor, 242, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, KOR, 13487
Qurient Co Ltd is a South Korea based biotech company. It is engaged in network research & development business model, integrating research and drug development programs with a new mechanism. Its pipeline products include Q301 for the treatment of atopic dermatitis; Q203 treats MDR/XDR/TDR TB, and Q701 is a drug-resistant cancer immuno-oncology.

Qurient Co Headlines

No Headlines